nishiyama yuya

This study aimed to develop a new, refined, and easy-to-use microvascular decompression surgical prosthesis and report its processability, uniformity, stability, and clinical safety.In an experimental study, the processing time required to create five slings and five balls from a prototype clump (0.010 ± 0.001 grams) was measured. Similarly, the processing time to form a clump (0.01 ± 0.001 grams) by plucking an equivalent amount of fibers from commercial polytetrafluoroethylene felt was measured. After approval from the Pharmaceuticals and Medical Devices Agency, the new prosthesis was used in 39 consecutive microvascular decompression surgeries.The handling time to make slings and balls from the refined polytetrafluoroethylene material was shorter than that from polytetrafluoroethylene felt (60.5 ± 4.81 versus 155 ± 6.59 seconds, p-value < 0.001 and 84.0 ± 8.51 versus 141.1 ± 7.02 seconds, p-value < 0.001). The tensile study showed that the prototype was significantly stronger than the slings conventionally made from polytetrafluoroethylene felt (6.2 ± 2.12 Newtons versus 1.56 ± 0.647 Newtons, p-value = 0.012). The adhesion study showed an equivalent adhesive strength to the conventional one (0.137 ± 0.05 Newtons versus 0.108 ± 0.05 Newtons, p-value = 0.40). The 39 microvascular decompression surgeries (trigeminal neuralgia, 13 cases; hemifacial spasm, 26 cases) showed no adverse events related to the materials (follow-up period: 9 months-3 years 9 months, mean: 2 years 9 months).The new Pharmaceuticals and Medical Devices Agency-approved, refined polytetrafluoroethylene material, which is easier to handle and less time-consuming, exhibited uniform characteristics, excellent manipulability, sufficient strength, and clinical reliability for prostheses. It may serve as a valuable additional option for prostheses in microvascular decompression surgery.

OBJECTIVE: Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms with a high propensity for local recurrence and extracranial metastasis. Although surgery and radiotherapy are the mainstays of treatment, systemic therapeutic options for recurrent disease remain limited. Pazopanib, a multitargeted tyrosine kinase inhibitor, has demonstrated clinical activity in extracranial SFTs; however, evidence in CNS SFTs is scarce. METHODS: We conducted a retrospective, single-institution study of patients with recurrent CNS SFTs treated with pazopanib. Clinical data, including prior treatments, imaging responses, treatment duration, and adverse events, were collected from medical records. Exploratory next-generation sequencing-based cancer panel testing was performed in two patients. RESULTS: Four patients with recurrent CNS SFTs were included. All had undergone prior surgical resection and radiotherapy. Pazopanib achieved partial response in one patient and stable disease in three patients, with treatment durations ranging from 7 months to over 2 years. One patient experienced disease progression after an initial period of response. Adverse events, including fatigue, gastrointestinal symptoms, and hypertension, were observed in all patients but were generally manageable with supportive care or dose adjustment. Exploratory molecular profiling identified various genomic alterations in two patients. CONCLUSIONS: In this single-institution retrospective series, pazopanib provided durable disease control with acceptable tolerability in selected patients with recurrent CNS SFTs. These findings support considering pazopanib as a systemic treatment option when further local therapies are not feasible, while highlighting the need for larger multicenter studies.